Relmada Therapeutics, Inc. (RLMD) key performance indicators and operating metrics (4 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| NDV-01 Complete Response Rate at Any Time | 95.00 percent | FY2026-Q1 |
| High-Risk Non-Muscle Invasive Bladder Cancer Complete Response Rate at Any Time | 95.00 percent | FY2026-Q1 |
| NDV-01 Complete Response Rate at Any Time (Bacillus Calmette–Guérin Unresponsive Subpopulation) | 94.00 percent | FY2026-Q1 |
| Bacillus Calmette–Guérin Unresponsive Non-Muscle Invasive Bladder Cancer Complete Response Rate at Twelve Months | 80.00 percent | FY2026-Q1 |
Back to RLMD overview · RLMD earnings · RLMD holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.